Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial. JAMA Neurol 75:1080–1088. https://doi.org/10.1001/jamaneurol.2018.1212

Article  PubMed  PubMed Central  Google Scholar 

Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia 38:1442–1454. https://doi.org/10.1177/s0333102418779543

Article  PubMed  Google Scholar 

Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A, Johnson KW, Shan Q, Carter J, Schacht A, Goadsby PJ, Dodick DW (2018) Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial. JAMA Neurol 75:187–193. https://doi.org/10.1001/jamaneurol.2017.3859

Article  PubMed  Google Scholar 

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. Neurology 91:e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camporeale A, Kudrow D, Sides R, Wang S, Van Dycke A, Selzler KJ, Stauffer VL (2018) A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine. BMC Neurol 18:188. https://doi.org/10.1186/s1288301811932

Article  PubMed  PubMed Central  Google Scholar 

Mulleners WM, Kim BK, Láinez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S, Tockhorn-Heidenreich A, Aurora SK, Nichols RM, Yunes-Medina L, Detke HC (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19:814–825. https://doi.org/10.1016/s14744422(20)302799

Article  CAS  PubMed  Google Scholar 

Sacco S, Braschinsky M, Ducros A, Lampl C, Little P, van den Brink AM, Pozo-Rosich P, Reuter U, de la Torre ER, Sanchez Del Rio M, Sinclair AJ, Katsarava Z, Martelletti P (2020) European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 21:76. https://doi.org/10.1186/s10194020011305

Article  PubMed  PubMed Central  Google Scholar 

Kwon S, Gil YE, Lee MJ (2022) Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients. Cephalalgia 42:705–714. https://doi.org/10.1177/s03331024221076481

Article  PubMed  Google Scholar 

Takizawa T, Ohtani S, Watanabe N, Miyazaki N, Ishizuchi K, Sekiguchi K, Iba C, Shibata M, Takemura R, Hori S, Nakahara J (2022) Real-world evidence ofgalcanezumab for migraine treatment in Japan: a retrospective analysis. BMC Neurol 22:512. https://doi.org/10.1186/s12883-022-03041-1

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P; GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https://doi.org/10.1186/s10194021012471

Article  Google Scholar 

Vernieri F, Brunelli N, Marcosano M, Aurilia C, Egeo G, Lovati C, Favoni V, Perrotta A, Maestrini I, Rao R, d’Onofrio L, Finocchi C, Aguggia M, Bono F, Ranieri A, Albanese M, Di Piero V, Cevoli S, Altamura C, Barbanti P; GARLIT Study Group (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study. Eur J Neurol 30:224–234

Article  Google Scholar 

Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S (2023) for the Italian Migraine Registry study group. Neurology 101:482–488. https://doi.org/10.1212/WNL.0000000000207292

Article  CAS  PubMed  Google Scholar 

Schwedt TJ, Tassorelli C, Silberstein SD, Szperka CL, Kurth T, Pozo-Rosich P, Amin FM, Lipton RB, Dodick DW, Ashina M, Diener HC, Terwindt GM (2022) Guidelines of the international headache society for clinic-based headache registries, 1st dition. Cephalalgia 42:1099–1115. https://doi.org/10.1177/s03331024221099035

Article  PubMed  PubMed Central  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, Initiative STROBE (2007) The Strengthening the REPORTING of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370:1453–1457. https://doi.org/10.1016/s01406736(07)61602-X

Article  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1–211. https://doi.org/10.1177/s0333102417738202.

Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Houle TT, Hoek TCVD, Martinelli D, Terwindt GM. International Headache Society Clinical Trials Committee (2020) Guidelines of the International Headache Societyfor controlled trials of preventive treatment of migraine attacks in episodic migraine in adults. Cephalalgia 40:1026–1044. https://doi.org/10.1177/s0333102420941839

Article  Google Scholar 

Shao J, Jordan DC, Pritchett YL (2009) Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat 19:672–684. https://doi.org/10.1080/s10543400902964118

Article  PubMed  Google Scholar 

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 57:289–300

Google Scholar 

Twisk JW, Rijnhart JJ, Hoekstra T, Schuster NA, Ter Wee MM, Heymans MW (2020) Intention-to-treat analysis when only a baseline value is available. Contemp Clin Trials Commun 20:100684. https://doi.org/10.1016/j.conctc.2020.100684

Article  PubMed  PubMed Central  Google Scholar 

Ashina S, Melo-Carrillo A, Toluwanimi A et al (2023) Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders. J Headache Pain 24:26. https://doi.org/10.1186/s10194-023-01560-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hu B, Li G, Li X, Wu S, Yu T, Li X, Zhao H, Jia Z, Zhuang J, Yu S (2022) Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain 23:90. https://doi.org/10.1186/s10194-022-01458-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou J, Zhong L, Chowdhury D et al (2023) Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study. J Headache Pain 2:103. https://doi.org/10.1186/s10194-023-01613-1

Article  CAS  Google Scholar 

Kim SA, Jang H, Lee MJ (2023) Predictors of galcanezumab response in a real-world study of Korean patients with migraine. Sci Rep 13:14825. https://doi.org/10.1038/s4159802342110-4

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hong JB, Lange KS, Fitzek M, Overeem LH, Triller P, Siebert A, Reuter U, Raffaelli (2023) Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany. J Headache Pain 24:144. https://doi.org/10.1186/s10194-023-01682-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee HC, Cho S, Kim BK (2023) Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. Neurol Sci 44:2455–2463. https://doi.org/10.1007/s10072023066832

Article  PubMed  Google Scholar 

Hong JB, Lange KS, Overeem LH, Triller P, Raffaelli B, Reuter U (2023) A scoping review and meta-analysis of Anti-CGRP monoclonal antibodies: predicting response. Pharmaceuticals 16:934. https://doi.org/10.3390/ph16070934

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbanti P, Egeo G, Aurilia C, Altamura C, d’Onofrio F, Finocchi C, Albanese M, Aguggia M, Rao R, Zucco M, Frediani F, Filippi M, Messina R, Cevoli S, Carnevale A, Fiorentini G, Messina S, Bono F, Torelli P, Proietti S, Bonassi S, Vernieri F, Registry IM, study group, (2022) Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients. J Headache Pain 23:138. https://doi.org/10.1186/s10194022014986

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muñoz-Vendrell A, Campoy S, Caronna E, Alpuente A, Torres-Ferrus M, Nieves Castellanos C, Olivier M, Campdelacreu J, Prat J, CamiñaMuñiz J, Molina Martínez FJ, Mínguez-Olaondo A, Ruibal Salgado M, Santos Lasaosa S, Navarro Pérez MP, Morollón N, López Bravo A, Cano Sánchez LM, García-Sánchez SM, García-Ull J, Rubio-Flores L, Gonzalez-Martinez A, Quintas S, EchavarríaÍñiguez A, Gil Luque S, Castro-Sánchez MV, Adell Ortega V, GarcíaAlhama J, Berrocal-Izquierdo N, Belvís R, Díaz-Insa S, Pozo-Rosich P, Huerta-Villanueva M (2023) Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. J Headache Pain 24:63. https://doi.org/10.1186/s10194023015852

Article  PubMed  PubMed Central  Google Scholar 

Mechtler L, Saikali N, McVige J, Hughes O, Traut A, Adams AM (2022) Real-World evidence for the safety and efficacy of CGRP monoclonal antibody therapy Added to OnabotulinumtoxinA treatment for Migraine prevention in adult patients with chronic migraine. Front Neurol 12:788159. https://doi.org/10.3389/fneur.2021.788159

Article  PubMed  PubMed Central  Google Scholar 

Blumenfeld AM, Frishberg BM, Schim JD, Iannone A, Schneider G, Yedigarova L, Manack Adams A (2021) Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA. A Retrospective Chart Revi Pain Ther 10:809–826. https://doi.org/10.1007/s4012202100264x

Article  Google Scholar 

Messina R, Huessler EM, Puledda F, Haghdoost F, Lebedeva ER, Diener HC (2023) safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: a systematic review and network meta-analysis. Cephalalgia 43:3331024231152169. https://doi.org/10.1177/s03331024231152169

Article  PubMed  Google Scholar